What is the best frontline therapy for patients with CLL and 17p deletion? - Wikidata - awgldk - TriplyDB

What is the best frontline therapy for patients with CLL and 17p deletion?

What is the best frontline therapy for patients with CLL and 17p deletion?

http://www.wikidata.org/entity/Q37820433

about

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.Personalized medicine in CLL: current status and future perspectives.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?What do we do with chronic lymphocytic leukemia with 17p deletion?TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

P2860

Q26775506-80326316-7241-4AB2-A2C6-E6AF6823A004 Q33419580-55DBFBE5-AF0D-4370-8B46-D45BE736C3BF Q33747801-F6BBFC13-4518-46CC-87AB-7B8EDA61B451 Q33978930-C26A950E-652A-4327-B436-A0424A248FC4 Q35054626-91AB9D91-C2D1-4BA1-ADC8-CE90AE6910C7 Q35806293-2F39916B-1E43-4475-9C5A-ACC710F5921F Q36416452-92350C92-5766-46DF-940F-219AC381ED7D Q37412148-0BB8F504-1633-45D3-918E-A0825C05068F Q37975154-B26F5389-40C1-45F8-A23A-AFB47B2D91CF Q38063170-95F067FC-EB86-47E3-9F27-A0ED2E91AC1E Q38177771-FB76EBA2-64BA-4ECD-B21D-BB0804626F10 Q38851368-C13C7DAC-D6F7-48BA-89ED-A01014FF18BF

P2860

What is the best frontline therapy for patients with CLL and 17p deletion?

http://www.wikidata.org/entity/Q37820433

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

What is the best frontline therapy for patients with CLL and 17p deletion?

@en

What is the best frontline therapy for patients with CLL and 17p deletion?

@nl

type

label

What is the best frontline therapy for patients with CLL and 17p deletion?

@en

What is the best frontline therapy for patients with CLL and 17p deletion?

@nl

prefLabel

What is the best frontline therapy for patients with CLL and 17p deletion?

@en

What is the best frontline therapy for patients with CLL and 17p deletion?

@nl

P1433

Q37820433-449449A1-99A0-42AA-B56B-EB5725BC1127

P1476

Q37820433-5D44C767-38DC-4A87-81FB-3ECB6DBA68F7

P2093

Q37820433-DF816312-6165-42B3-9862-817BB66A7CAB

P2860

Q37820433-0456E217-ADC9-4A75-BC7B-C371A72547FD

Q37820433-0615B3A7-77E9-4666-AD46-A88495511005

Q37820433-0ACB75BB-C070-4080-8044-AF2CFDB6C615

Q37820433-0C6389E5-0096-4C28-B44E-FAA2CB675B6F

Q37820433-0E166DA6-903F-41B8-9CAC-C1D38267C37D

Q37820433-0E3DE738-C174-4C2E-9523-2474C8F40E4A

Q37820433-10CBB54D-BB61-4D82-AA4B-0352C06EB4A6

Q37820433-125BC21B-B80D-4FDF-831A-237D2C1635C2

Q37820433-1627C111-BE6F-4775-97D7-7F4A92B87BCD

Q37820433-1945B7B1-AD77-49EC-B472-3CBAC3988924

P2888

Q37820433-DBE81F3F-77F1-4A53-8825-CC95D10F4BBE

P304

Q37820433-187CE86B-212E-4494-9A23-0EB30F3EBC2B

P31

Q37820433-25405439-06AE-4EB8-909E-1CD9B890C3BA

Q37820433-40f1e835-49b2-496a-9a10-ebe69935e46e

P356

Q37820433-3C0525D3-7B07-4380-BD1C-196717AB006E

P433

Q37820433-D121343B-BA7D-4605-BB99-6A59AA7E38DC

P478

Q37820433-FD600B49-B313-463A-8CD4-227752B7A2F0

P50

Q37820433-A852A62F-FFD1-4C5C-AD4B-1D323885C23C

Q37820433-DE569233-151B-4E05-856A-A8AD7D4CADCA

P577

Q37820433-DB3B8614-347D-40ED-95FF-5CFF7D9CCD63

P698

Q37820433-FC887CC5-73A3-402E-9408-99889FE6D0F2

P356

S11899-010-0069-3

P1433

Current hematologic malignancy reports

P1476

What is the best frontline therapy for patients with CLL and 17p deletion?

@en

P2093

Xavier C Badoux

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

TP53 mutation and survival in chronic lymphocytic leukemia.

p53, the cellular gatekeeper for growth and division

Genomic aberrations and survival in chronic lymphocytic leukemia

p53 mutations in human cancers

The p53 pathway: positive and negative feedback loops

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients.

P2888

s11899-010-0069-3

P304

36-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-010-0069-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

Michael J. Keating

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21153774

http://www.w3.org/2001/XMLSchema#string